CT Radiomics for Predicting Outcomes in HER2-Positive Surgically Resectable Advanced Gastric Cancer: A Preliminary Study.
[RATIONALE AND OBJECTIVES] Accurate risk stratification in human epidermal growth factor receptor 2-positive surgically resectable advanced gastric cancer (HER2-p SRAGC) can strengthen monitoring for
- 표본수 (n) 330
- p-value p<0.001
- p-value p=0.009
- 95% CI 0.585-0.753
APA
Zhao H, Gao J, et al. (2025). CT Radiomics for Predicting Outcomes in HER2-Positive Surgically Resectable Advanced Gastric Cancer: A Preliminary Study.. Academic radiology, 32(9), 5254-5266. https://doi.org/10.1016/j.acra.2025.05.009
MLA
Zhao H, et al.. "CT Radiomics for Predicting Outcomes in HER2-Positive Surgically Resectable Advanced Gastric Cancer: A Preliminary Study.." Academic radiology, vol. 32, no. 9, 2025, pp. 5254-5266.
PMID
40461325
Abstract
[RATIONALE AND OBJECTIVES] Accurate risk stratification in human epidermal growth factor receptor 2-positive surgically resectable advanced gastric cancer (HER2-p SRAGC) can strengthen monitoring for high-risk patients, allowing timely HER2-specific treatment and potentially improving prognosis. Therefore, we aimed to develop a CT radiomics model for predicting outcomes in HER2-p SRAGC and compare it with the 8th edition TNM staging system.
[MATERIALS AND METHODS] 621 HER2-p SRAGC patients who received either radical gastrectomy or radical gastrectomy after neoadjuvant therapy or chemotherapy were retrospectively enrolled in two hospitals and assigned to a training (n=330), an internal validation (n=143) and an external validation (n=148) cohorts. A radiomics model incorporating Radscore and clinical scores was constructed. Model performance was assessed by Kaplan-Meier estimator, Log-rank test, and Harrell's C-index.
[RESULTS] The radiomics model was correlated with the overall survival (OS) across all cohorts, with C-indexes of 0.711[95% confidence interval (CI): 0.666-0.756; p<0.001; training], 0.669 (95%CI: 0.585-0.753; p=0.009; internal validation) and 0.693 (95%CI: 0.597-0.789; p=0.015; external validation). In all study cohorts, the radiomics model successfully stratified patients into high-risk and low-risk groups, and outweighed individual scores, pathological staging (pTNM), and clinical staging (cTNM) but was inferior to post-neoadjuvant therapy staging (ypTNM). Additionally, the radiomics model had added value to the prognostic efficacy of pTNM and was unaffected by patient age and gender.
[CONCLUSION] The radiomics model delivers individualized prognosis prediction of HER2-p SRAGC, surpassing clinical scores, and both pTNM and cTNM in forecasting OS. It confers incremental benefit to pTNM and exhibits certain universality across patient types.
[TRIAL REGISTRATION] Retrospectively registered.
[MATERIALS AND METHODS] 621 HER2-p SRAGC patients who received either radical gastrectomy or radical gastrectomy after neoadjuvant therapy or chemotherapy were retrospectively enrolled in two hospitals and assigned to a training (n=330), an internal validation (n=143) and an external validation (n=148) cohorts. A radiomics model incorporating Radscore and clinical scores was constructed. Model performance was assessed by Kaplan-Meier estimator, Log-rank test, and Harrell's C-index.
[RESULTS] The radiomics model was correlated with the overall survival (OS) across all cohorts, with C-indexes of 0.711[95% confidence interval (CI): 0.666-0.756; p<0.001; training], 0.669 (95%CI: 0.585-0.753; p=0.009; internal validation) and 0.693 (95%CI: 0.597-0.789; p=0.015; external validation). In all study cohorts, the radiomics model successfully stratified patients into high-risk and low-risk groups, and outweighed individual scores, pathological staging (pTNM), and clinical staging (cTNM) but was inferior to post-neoadjuvant therapy staging (ypTNM). Additionally, the radiomics model had added value to the prognostic efficacy of pTNM and was unaffected by patient age and gender.
[CONCLUSION] The radiomics model delivers individualized prognosis prediction of HER2-p SRAGC, surpassing clinical scores, and both pTNM and cTNM in forecasting OS. It confers incremental benefit to pTNM and exhibits certain universality across patient types.
[TRIAL REGISTRATION] Retrospectively registered.
MeSH Terms
Humans; Stomach Neoplasms; Female; Male; Middle Aged; Retrospective Studies; Tomography, X-Ray Computed; Erb-b2 Receptor Tyrosine Kinases; Neoplasm Staging; Aged; Gastrectomy; Prognosis; Neoadjuvant Therapy; Adult; Radiomics
같은 제1저자의 인용 많은 논문 (5)
- Beyond Epilepsy Control: Repurposing Antiepileptic Drugs in Central Nervous System Tumor Therapy.
- Mechanisms Influencing Neoadjuvant Treatment Decision-Making in Patients With Locally Advanced Gastric Cancer: An Analysis Based on the Ottawa Decision Support Framework.
- Dysregulated inflammatory cytokines in MSM living with HIV who exhibited suboptimal immune reconstitution despite antiretroviral therapy (ART).
- SUMOylation and anticancer drug resistance.
- F-FDG PET-based ensemble deep learning model for the prediction of lymphovascular invasion in colorectal cancer patients.